KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $298000.0.

  • Twist Bioscience's Cash from Financing Activities fell 9833.93% to $298000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $10.9 million, marking a year-over-year decrease of 5858.9%. This contributed to the annual value of $28.5 million for FY2025, which is 31422.35% up from last year.
  • As of Q4 2025, Twist Bioscience's Cash from Financing Activities stood at $298000.0, which was down 9833.93% from $5.6 million recorded in Q3 2025.
  • Over the past 5 years, Twist Bioscience's Cash from Financing Activities peaked at $271.6 million during Q1 2022, and registered a low of -$1.5 million during Q4 2023.
  • Its 5-year average for Cash from Financing Activities is $15.5 million, with a median of $1.5 million in 2021.
  • In the last 5 years, Twist Bioscience's Cash from Financing Activities soared by 1861922.81% in 2022 and then tumbled by 27291.14% in 2023.
  • Quarter analysis of 5 years shows Twist Bioscience's Cash from Financing Activities stood at -$1.0 million in 2021, then skyrocketed by 60.93% to -$395000.0 in 2022, then crashed by 272.91% to -$1.5 million in 2023, then skyrocketed by 1318.19% to $17.9 million in 2024, then plummeted by 98.34% to $298000.0 in 2025.
  • Its last three reported values are $298000.0 in Q4 2025, $5.6 million for Q3 2025, and $1.8 million during Q2 2025.